Loading...
Transgene SA
TRGNF•PNK
Healthcare
Biotechnology
$0.70
$0.00(0.00%)
Transgene SA (TRGNF) Financial Performance & Income Statement Overview
Review Transgene SA’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-96.11%
↓ 96.11%
Operating Income Growth
-18.67%
↓ 18.67%
Net Income Growth
-52.15%
↓ 52.15%
Operating Cash Flow Growth
32.08%
↑ 32.08%
Operating Margin
-1093.13%
↓ 1093.13%
Gross Margin
-831.71%
↓ 831.71%
Net Profit Margin
-725.03%
↓ 725.03%
ROE
-314.11%
↓ 314.11%
ROIC
-122.54%
↓ 122.54%
Transgene SA (TRGNF) Income Statement & Financial Overview
Review Transgene SA's (TRGNF) income statement with detailed quarterly and annual figures.
| Metric | Q2 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $23000.00 | $1.57M | $1.57M | $1.16M |
| Cost of Revenue | $0.00 | $7.010M | $7.010M | $7.78M |
| Gross Profit | $23000.00 | -$5.44M | -$5.44M | -$6.63M |
| Gross Profit Ratio | $1.00 | -$3.47 | -$3.47 | -$5.73 |
| R&D Expenses | $14.83M | $8.66M | $8.66M | $14.79M |
| SG&A Expenses | $4.54M | $1.87M | $1.87M | $3.22M |
| Operating Expenses | $19.25M | $1.92M | $1.92M | $18.02M |
| Total Costs & Expenses | $19.85M | $8.93M | $8.93M | $18.82M |
| Interest Income | $311000.00 | $0.00 | $3.75M | $249000.00 |
| Interest Expense | $542000.00 | $0.00 | $0.00 | $39000.00 |
| Depreciation & Amortization | $606000.00 | $607500.00 | $607500.00 | $803000.00 |
| EBITDA | -$18.54M | -$6.73M | -$6.73M | -$7.27M |
| EBITDA Ratio | -$806.26 | -$4.29 | -$4.29 | -$14.59 |
| Operating Income | -$19.83M | -$7.36M | -$7.34M | -$17.66M |
| Operating Income Ratio | -$862.13 | -$4.69 | -$4.68 | -$15.28 |
| Other Income/Expenses (Net) | $137000.00 | $4.14M | $4.14M | $9.71M |
| Income Before Tax | -$19.69M | -$3.21M | -$3.21M | -$19.37M |
| Income Before Tax Ratio | -$856.17 | -$2.05 | -$2.05 | -$16.75 |
| Income Tax Expense | -$3.21M | -$2.98M | $0.00 | -$3.46M |
| Net Income | -$16.48M | -$3.21M | -$3.21M | -$15.90M |
| Net Income Ratio | -$716.74 | -$2.05 | -$2.05 | -$13.76 |
| EPS | -$0.16 | -$0.03 | -$0.03 | -$0.16 |
| Diluted EPS | -$0.16 | -$0.03 | -$0.03 | -$0.16 |
| Weighted Avg Shares Outstanding | $100.96M | $101.39M | $101.39M | $99.80M |
| Weighted Avg Shares Outstanding (Diluted) | $100.96M | $101.38M | $101.38M | $99.80M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan